<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04503707</url>
  </required_header>
  <id_info>
    <org_study_id>000370</org_study_id>
    <nct_id>NCT04503707</nct_id>
  </id_info>
  <brief_title>Study to Assess the Design of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures in Routine Clinical Practice</brief_title>
  <acronym>DELTA</acronym>
  <official_title>French Prospective Multicentre Non-Interventional Study to Assess the Design of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures in Routine Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to explore how the individualized dosing regimen of REKOVELLE is used&#xD;
      in routine clinical practice and to describe the effectiveness and safety of REKOVELLE under&#xD;
      real-world conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 17, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Daily dose of REKOVELLE administered (for naïve and non-naïve subjects)</measure>
    <time_frame>At the end of the stimulation protocol (up to 30 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of treatment with REKOVELLE (for naïve and non-naïve subjects)</measure>
    <time_frame>From first until last day of REKOVELLE treatment (up to 30 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Use of the dosing App (for naïve and non-naïve subjects)</measure>
    <time_frame>At visit when the daily dose of REKOVELLE is decided (up to 2 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of Gonadotropin-Releasing Hormone (GnRH) used (for naïve and non-naïve subjects)</measure>
    <time_frame>At visit (up to 2 hours) during the REKOVELLE treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of treatment with GnRH (for naïve and non-naïve subjects)</measure>
    <time_frame>At the end of the ovarian controlled stimulation (up to 2 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment used for the triggering of follicle maturation (for naïve and non-naïve subjects)</measure>
    <time_frame>At the last visit during the REKOVELLE treatment period (from 5 to 30 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment used for Luteal phase support (for naïve and non-naïve subjects)</measure>
    <time_frame>From start of REKOVELLE treatment until 10-11 weeks after embryo transfer</time_frame>
    <description>Decided as a choice between Progesterone, Oestrogen and hCG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Ongoing Pregnancy (for naïve and non-naïve subjects)</measure>
    <time_frame>Up to 10-11 weeks after transfer</time_frame>
    <description>Ongoing pregnancy is defined as at least one intrauterine viable fetus, 10-11 weeks after first fresh or frozen embryo/blastocyst transfer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes retrieved (for naïve and non-naïve subjects)</measure>
    <time_frame>At visit (up to 2 hours) at 36 hours after completed REKOVELLE treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes/embryos/blastocysts frozen (for naïve and non-naïve subjects)</measure>
    <time_frame>At Day 3 after oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of fresh or frozen embryos or blastocysts transferred (excellent, good, fair, other) (for naïve and non-naïve subjects)</measure>
    <time_frame>At Day 3, 5 or 6 after oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate (for naïve and non-naïve subjects)</measure>
    <time_frame>Up to 10-11 weeks after transfer</time_frame>
    <description>Implantation rate is defined as number of intrauterine viable fetus after transfer divided by the number of embryos/blastocysts transferred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive human chorionic gonadotropin (hCG) test (for naïve and non-naïve subjects)</measure>
    <time_frame>Up to 10-11 weeks after transfer</time_frame>
    <description>Proportion of subjects with positive hCG test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate (for naïve and non-naïve subjects)</measure>
    <time_frame>Up to 5-6 weeks after transfer</time_frame>
    <description>Clinical pregnancy is defined as least one gestational sac.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of biochemical pregnancy (for naïve and non-naïve subjects)</measure>
    <time_frame>Up to 10-11 weeks after transfer</time_frame>
    <description>Biochemical pregnancy is defined as positive beta hCG (βhCG) test but no gestational sac is observed on later transvaginal ultrasound, or menstruation is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of spontaneous abortion (for naïve and non-naïve subjects)</measure>
    <time_frame>Up to 10-11 weeks after transfer</time_frame>
    <description>Spontaneous abortion is defined as positive βhCG test but all intrauterine gestational sacs without fetal heart beat as documented by ultrasound, or there are no viable fetuses observed by ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of elective abortion (for naïve and non-naïve subjects)</measure>
    <time_frame>Up to 10-11 weeks after transfer</time_frame>
    <description>Elective abortion is defined as induced abortion done at the request of the woman for other than therapeutic reasons.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of vanishing twins (for naïve and non-naïve subjects)</measure>
    <time_frame>Up to 10-11 weeks after transfer</time_frame>
    <description>Vanishing twin is defined as spontaneous disappearance of an intrauterine gestational sac with or without heart beat in a pregnancy where one viable fetus remains as documented by ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ectopic pregnancy (for naïve and non-naïve subjects)</measure>
    <time_frame>Up to 10-11 weeks after transfer</time_frame>
    <description>Ectopic pregnancy is defined as extrauterine gestational sac with or without fetal heart beat as documented by ultrasound or surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with cycle cancellation (for naïve and non-naïve subjects)</measure>
    <time_frame>Up to 10-11 weeks after transfer</time_frame>
    <description>Cancellation could be done before oocyte pick up (due to poor ovarian response, excessive ovarian response, any illness which prevents oocyte collection procedure, subject not taking hCG injection at the correct time, subject choice, other) or after oocyte pick up (due to no oocytes collected, no oocytes fertilized, abnormal fertilization, abnormal embryo development, no embryo development, ovarian hyperstimulation syndrome (OHSS), subject choice, other)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of gonadotropin used (previous cycle information for non-naïve subjects)</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of gonadotropin used (previous cycle information for non-naïve subjects)</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment with gonadotropin (previous cycle information for non-naïve subjects)</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of GnRH used (previous cycle information for non-naïve subjects)</measure>
    <time_frame>At baseline</time_frame>
    <description>Defined as a choice between GnRH agonist and GnRH antagonist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment with GnRH (previous cycle information for non-naïve subjects)</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment used for the triggering of follicle maturation (previous cycle information for non-naïve subjects)</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment used for Luteal phase support (previous cycle information for non-naïve subjects)</measure>
    <time_frame>At baseline</time_frame>
    <description>Decided as a choice between Progesterone, Oestrogen and hCG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes retrieved (previous cycle information for non-naïve subjects)</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of embryos/blastocysts transferred (previous cycle information for non-naïve subjects)</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pregnancy loss in women with embryo/blastocyst transfer (previous cycle information for non-naïve subjects)</measure>
    <time_frame>At baseline</time_frame>
    <description>Pregnancy loss included biochemical pregnancy, spontaneous / elective abortion, ectopic pregnancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with OHSS including moderate/severe grade (previous cycle information for non-naïve subjects)</measure>
    <time_frame>At baseline</time_frame>
    <description>Each OHSS case will be classified as moderate or severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with preventive interventions for early OHSS (previous cycle information for non-naïve subjects)</measure>
    <time_frame>At baseline</time_frame>
    <description>Preventive interventions cover triggering of final follicular maturation with GnRH agonist and fresh embryo/blastocyst transfer or cryopreservation of oocytes/embryos/blastocysts, cycle cancellation, coasting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with preventive interventions for early OHSS (for naïve and non-naïve subjects)</measure>
    <time_frame>Up to 10-11 weeks after transfer</time_frame>
    <description>Preventive interventions cover triggering of final follicular maturation with GnRH agonist and fresh embryo/blastocyst transfer or cryopreservation of oocytes/embryos/blastocysts, Cycle cancellation, Coasting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse drug reactions (ADR) (for naïve and non-naïve subjects)</measure>
    <time_frame>From start of REKOVELLE treatment until 10-11 weeks after embryo transfer</time_frame>
    <description>An ADR is characterized by the causal relationship between REKOVELLE and the adverse event is at least a reasonable possibility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of the REKOVELLE treatment (number and intents of each visit) (for naïve and non-naïve subjects)</measure>
    <time_frame>From Day 1 up to the last day of REKOVELLE stimulation</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">250</enrollment>
  <condition>Controlled Ovarian Stimulation</condition>
  <arm_group>
    <arm_group_label>Follitropin Delta</arm_group_label>
    <description>Treatment according to routine clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin Delta</intervention_name>
    <description>The Intervention (solution for injection) is delivered with a pre-filled injection pen. The REKOVELLE dose will be based on a recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the ELECSYS AMH Plus Immunoassay.</description>
    <arm_group_label>Follitropin Delta</arm_group_label>
    <other_name>REKOVELLE</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women who are prescribed REKOVELLE within the approved indication for in vitro&#xD;
        fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment will be invited to&#xD;
        participate in the study. Subjects will be enrolled only after the treatment decision has&#xD;
        been made and no aspect of this study will interfere with or influence the routine medical&#xD;
        procedures and/or medications received.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females aged 18 years or older at enrolment&#xD;
&#xD;
          -  Who are treated for IVF or ICSI treatment cycle using fresh or frozen ejaculated sperm&#xD;
             from male partner or sperm donor&#xD;
&#xD;
          -  Who are prescribed REKOVELLE for the first time and using the dosing algorithm to&#xD;
             define the dose regimen: a previous cycle with REKOVELLE should not be allowed&#xD;
&#xD;
          -  Who have been informed verbally and in writing about this study content and who do not&#xD;
             object to their data being electronically processed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participating in an interventional clinical trial in which any treatment or follow-up&#xD;
             is mandated&#xD;
&#xD;
          -  Women with a contraindication for prescription of REKOVELLE treatment&#xD;
&#xD;
          -  Oocyte donors&#xD;
&#xD;
          -  Women undergoing ovarian stimulation for fertility preservation&#xD;
&#xD;
          -  Women undergoing their third or fourth attempt of IVF or ICSI for the current parental&#xD;
             project.&#xD;
&#xD;
          -  Subject non-affiliated to French Social Security&#xD;
&#xD;
          -  Women placed under judicial protection, guardianship, or supervision&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Compliance</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Femme Mère Enfant</name>
      <address>
        <city>BRON cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Antoine Béclère</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Créteil</name>
      <address>
        <city>Creteil Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Lille-Hopital de Flandre</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Médecine de la Reproduction (there may be other sites in this country)</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes Hôpital Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maternité Port Royal</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Poissy</name>
      <address>
        <city>Poissy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste La Sagesse</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierre OGER</name>
      <address>
        <city>Rueil-Malmaison</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMCO</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hôpital Paule de Viguier</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Follicle Stimulating Hormone (FSH)</keyword>
  <keyword>Assisted Reproductive Technologies (ART)</keyword>
  <keyword>Follitropin Delta</keyword>
  <keyword>REKOVELLE</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

